PRODUCT IDENTIFICATION

H.S. CODE

TOXICITY

(e)-N-(6,6-Dimethyl-2-hepten-4-ynyl)- N-methyl- 1- naphthalenemethanamine hydrochloride; N,6,6-Trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine hydrochloride; ((2E)-6,6-Dimethylhept-2-en-4-yn-1-yl)(methyl)(naphthalen-1-ylmethyl)amine;  trans-N-(6,6-Dimethyl-2-hepten-4-ylyl)-N-methyl-1-naphthylmethylamine hydrochloride;

SMILES

CLASSIFICATION

Allylamine, Anti-infective, Antifungal, Enzyme Inhibitor, Antibiotic, Antimycobacterial.

PHYSICAL AND CHEMICAL PROPERTIES

AUTOIGNITION

NFPA RATINGS

REFRACTIVE INDEX

GENERAL DESCRIPTION & EXTERNAL LINKS

Terbinafine is a broad-spectrum antifungal agent. It belongs to the family of allylamine structure antifungal agent such as amorolfine, naftifine, butenafine which interferes with biosynthesis of ergosterol needed for the fungal cell membrane. Allylamine antifungal agents are highly lipophilic and are applied topically to the skin, nails, and fatty tissues. Chemically terbinafine is (e)-N-(6,6-dimethyl-2-hepten-4-ynyl)- N-methyl- 1- naphthalenemethanamine. Terbinafine hydrochloride is a white to off- white fine crystalline powder; slightly soluble in water, freely soluble in lower alcohol and methylene chloride. Terbinafine is also used as a trypanocidal agent.

Wikipedia Linking: http://en.wikipedia.org/wiki/Terbinafine

http://www.jornaldepneumologia.com.br/
In clinical practice, there are few drugs used to control the various fungal infections of the respiratory tract. Sulfonamides, which are effective against only a few agents, were the first drugs used in the treatment of patients with systemic mycosis, being first administered around 1940. In the decade that followed, amphotericin B became available. Its antifungal spectrum and efficacy have placed it (and held it) in the position of the drug of choice for the control of visceral and disseminated infections. Although of little use in isolation, 5-fluorocytosine was considered to work in synergy with amphotericin B, especially against cryptococci. The clinical use of azole drugs began in the mid-1970s. Due to their broad spectrum of action, and after the development of cetoconazole, their easy oral administration, these drugs had a great impact on antifungal therapy. In the 1990s, the imidazoles were joined by the triazoles (fluconazole and itraconazole), which presented greater bioavailability and a more intense effect. Voriconazole, a second generation triazole with a broader spectrum of action than the previous azoles, was recently was approved for medical use. Other new derivates, such as posaconazole and ravuconazole, are still awaiting approval. In the last 15 years, lipid formulations of amphotericin B have been developed. In addition, there are two new classes of antifungal agents: the allylamines, represented by terbinafine, with greater use for both skin and nail mycosis; and the echinocandins, of which caspofungin is the most well known in Brazil.

http://jcm.asm.org/
The in vitro activities of voriconazole against 19 different species of dermatophytes were compared with those of terbinafine, itraconazole, ketoconazole, griseofulvin, and fluconazole. MICs were determined according to a National Committee for Clinical Laboratory Standards broth macrodilution method. Voriconazole appeared more active than ketoconazole, griseofulvin, and fluconazole and less active than itraconazole and terbinafine. Based on these results, voriconazole merits further investigation as a potentially useful agent for the treatment of dermatophytosis.

APPEARANCE

99.0 - 101.0%

195 - 198 C

IMPURITY

0.5% max

0.5% max